ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1154

Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement

Yinzhu Jin1, Daniel Solomon1,2, Patricia D. Franklin3, Yvonne C. Lee4, Joyce Lii1, Jeffrey N. Katz5 and Seoyoung C. Kim6,7, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Musculoskeletal Center of Excellence, University of Massachusetts Medical School, Worcester, MA, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Joint replacement, opioids and pain management

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with moderate-to-severe hip or knee arthritis often use opioids before undergoing total joint replacement (TJR). Preoperative opioid use may lead to persistent opioid use and poor clinical outcomes after TJR. We aimed to describe patterns of opioid use before TJR.

Methods:

Using Medicare (Parts A/B/D, 2010-2014) data, we conducted a cohort study among patients aged ≥65 who underwent incident total hip replacement (THR) or total knee replacement (TKR). Index date was the incident TJR date. Eligible patients were required to have continuous enrollment in Part A/B/D for at least 360 days before the index date. We excluded patients with: 1) no medical and/or pharmacy claims in the 360-days before the index date, and 2) both THR and TKR on the same date. Any opioid use was defined as having ≥1 opioid dispensing during the 12-month period; continuous opioid use was characterized as having ≥1 opioid dispensing in each of 12 months during the before the index date. We calculated mean morphine milligram equivalent (MME) per day and proportion of days covered (PDC) in each month. 50 MME is equivalent to 50 mg hydrocodone. We assessed variables potentially associated with opioid use, such as demographics, pain/fractures, other comorbidities, medication use, and healthcare use in 360 days prior to the surgery. A multivariable logistic regression model estimated the associations between patient characteristics and preoperative opioid use patterns.

Results:

We identified a total of 473,781 patients who underwent TJR: 155,516 THR and 318,265 TKR.  Mean (SD) age was 75 (7) years for THR and 74 (6) for TKR patients. 67.4% were female and 91.5% were White. Back pain was a common comorbidity in both THR (62%) and TKR (46.8) patients. 60.2% patients had any use of opioids before the surgery. Of those, 12.4% used opioids at least once a month continuously over the 12-month preoperative period. Hydrocodone was most commonly used agent, followed by tramadol and oxycodone. Among any users of opioids, MME per day and PDC both increased toward the TJR date. Continuous opioid users had over 90% PDC in the month before TJR and used higher MME dose of opioids per day (58mg in THR, 51mg in TKR) compared to any users (16mg in THR, 12mg in TKR) (p-values <0.0001) (Figure). Correlates of continuous opioid use included history of drug abuse (OR=5.19, 95% CI=3.96-6.84) and back pain (OR=2.32, 95% CI=2.24-2.40). African American patients had a 2-fold higher odds of using opioid continuously compared with White Americans (OR=2.14, 95% CI=2.01-2.28).

Conclusion:

Among patients in Medicare who underwent TJR, 60.2% had any use of opioids and 7.5% had continuous use of opioids in the year before the surgery. Use of opioids and MME increased gradually toward the index TJR date. History of drug abuse, back pain, and race African American were strongly associated with continuous use of opioids preoperatively.

 


Disclosure: Y. Jin, None; D. Solomon, None; P. D. Franklin, None; Y. C. Lee, None; J. Lii, None; J. N. Katz, None; S. C. Kim, None.

To cite this abstract in AMA style:

Jin Y, Solomon D, Franklin PD, Lee YC, Lii J, Katz JN, Kim SC. Patterns of Opioid Use and Patient Characteristics before Total Hip and Knee Replacement [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/patterns-of-opioid-use-and-patient-characteristics-before-total-hip-and-knee-replacement/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-opioid-use-and-patient-characteristics-before-total-hip-and-knee-replacement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology